The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy (original) (raw)

• Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501–1512 (1999).
  Article CAS PubMed Google Scholar
• Hengst, L. & Reed, S. I. Inhibitors of the Cip/Kip family. Curr. Top. Microbiol. Immunol. 227, 25–41 (1998)
  CAS PubMed Google Scholar
• Nigg, E. A. Targets of cyclin-dependent protein kinases. Curr. Opin. Cell Biol. 199, 187–193 (1993).
  Article Google Scholar
• James, M., Ray, A., Leznova, D. & Blain, S. W. Differential modification of p27Kip1 controls its cyclin D–cdk4 inhibitory activity. Mol. Cell Biol. (2007). Showed that p27 in active cyclin D1–CDK4 complexes is phosphorylated on tyrosine whereas p27 in catalytically inactive cyclin D1–CDK4 is not.
• Grimmler, M. et al. Cdk-inhibitory activity and stability of p27 Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 128, 269–280 (2007).
  Article CAS PubMed Google Scholar
• Hengst, L. & Reed, S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science 271, 1861–1864 (1996). This paper demonstrated that CDKN1B transcript levels vary little, but translation is maximal in quiescence and falls during G1 progression.
  Article CAS PubMed Google Scholar
• Liang, J. & Slingerland, J. M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2, 339–345 (2003).
  Article CAS PubMed Google Scholar
• Besson, A., Assoian, R. K. & Roberts, J. M. Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nature Rev. Cancer 4, 948–955 (2004). An important review of primary work by these authors and others showing that cytoplasmic p27 has effects on cell motility that are, at least in part, independent of its Cdk regulatory functions.
  Article CAS Google Scholar
• Slingerland, J. & Pagano, M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell Physiol. 183, 10–17 (2000).
  Article CAS PubMed Google Scholar
• Medema, R. H., Kops, G. J., Bos, J. L. & Burgering, B. M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404, 782–787 (2000).
  Article CAS PubMed Google Scholar
• Dijkers, P. F. et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27KIP1. Mol. Cell. Biol. 20, 9138–9148 (2000). References 10 and 11 were the first to show that p27 transcription is opposed by Akt action on forkhead transcription factors.
  Article CAS PubMed PubMed Central Google Scholar
• Trotman, L. C. et al. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441, 523–527 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, H. L., Zhao, R. Y., Yang, H. Y. & Lee, M. H. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene 24, 1924–1935 (2005).
  Article CAS PubMed Google Scholar
• Wang, X. H. et al. Increased hepatic forkhead box M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration through diminished p27(KiP1) protein levels and increased Cdc25B expression. J. Biol. Chem. 277, 44310–44316 (2002).
  Article CAS PubMed Google Scholar
• Karnik, S. K. et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27(Kip1) and p18(INK4c). Proc. Natl Acad. Sci. USA 102, 14659–14664 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Fontaniere, S., Casse, H., Bertolino, P. & Zhang, C. X. Analysis of p27Kip1 expression in insulinomas developed in pancreatic β-cell specific Men1 mutant mice. Familial Cancer 5, 49–54 (2006).
  Article CAS PubMed Google Scholar
• Pellegata, N. S. et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA 103, 15558–15563 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Georgitsi, M. et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br. J. Cancer 96, 352–356 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, W. et al. Repression of transcription of the p27Kip1 cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20, 1688–1702 (2001).
  Article CAS PubMed Google Scholar
• O'Hagan, R. C. et al. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 14, 2185–2191 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Keller, U. B. et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 26, 2562–2574 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, C. G. et al. Activation of p27Kip1 expression by E2F1 — a negative feedback mechanism. J. Biol. Chem. 280, 12339–12343 (2005).
  Article CAS PubMed Google Scholar
• Inoue, T., Kamiyama, J. & Sakai, T. Sp1 and NF-Y synergistically mediate the effect of vitamin D-3 in the p27Kip1 gene promoter that lacks vitamin D response elements. J. Biol. Chem. 274, 32309–32317 (1999).
  Article CAS PubMed Google Scholar
• Murata, K. et al. Hes1 directly controls cell proliferation through the transcriptional repression of p27Kip1. Mol. Cell. Biol. 25, 4262–4271 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, Y. C., Chen, J. Y. & Hung., W. C. Vitamin D-3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D-3. Oncogene 23, 4856–4861 (2004).
  Article CAS PubMed Google Scholar
• Agrawal, D. et al. Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol. Cell Biol. 16, 4327–4336 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Millard, S. S. et al. Enhanced ribosomal association of p27Kip1 mRNA is a mechanism contributing to accumulation during growth arrest. J. Biol. Chem. 272, 7093–7098 (1997).
  Article CAS PubMed Google Scholar
• Gopfert, U., Kullmann, M. & Hengst, L. Cell cycle-dependent translation of p27 involves a responsive element in its 5′-UTR that overlaps with a uORF. Hum. Mol. Genet. 12, 1767–1779 (2003).
  Article PubMed CAS Google Scholar
• Miskimins, W. K., Wang, G., Hawkinson, M. & Miskimins, R. Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation. Mol. Cell. Biol. 21, 4960–4967 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Kullmann, M., Gopfert, U., Siewe, B. & Hengst, L. ELAV/Hu proteins inhibit p27 translation via an IRES element in the p27 5′ UTR. Genes Dev. 16, 3087–3099 (2002). Showed ELAV /Hu proteins bind an IRES in the 5′ UTR to impair p27 translation. Overexpression of ELAV in cancers might reduce p27 translation and contribute to development or progression of certain cancers.
  Article CAS PubMed PubMed Central Google Scholar
• Yoon, A. et al. Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science 312, 902–906 (2006).
  Article CAS PubMed Google Scholar
• Cho, S. C., Kim, J. H., Back, S. H. & Jang, S. K. Polypyrimidine tract-binding protein enhances the internal ribosomal entry site-dependent translation of p27Kip1 mRNA and modulates transition from G1 to S phase. Mol. Cell. Biol. 25, 1283–1297 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Millard, S. S., Vidal, A., Markus, M. & Koff, A. A U-rich element in the 5′ untranslated region is necessary for the translation of p27 mRNA. Mol. Cell Biol. 20, 5947–5959 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Erkinheimo, T. L. et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 63, 7591–7594 (2003).
  CAS PubMed Google Scholar
• Denkert, C. et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res. 64, 189–195 (2004).
  Article CAS PubMed Google Scholar
• de Silanes, I. L. et al. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 22, 7146–7154 (2003).
  Article CAS Google Scholar
• Vidal, A., Millard, S. S., Miller, J. P. & Koff, A. Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status. J. Biol. Chem. 277, 16433–16440 (2002).
  Article CAS PubMed Google Scholar
• Gonzalez, T. et al. Inhibition of Cdk4 activity enhances translation of p27kip1 in quiescent Rb-negative cells. J. Biol. Chem. 278, 12688–12695 (2003).
  Article CAS PubMed Google Scholar
• le Sage, C., Nagel, R. & Agami, R. Diverse ways to control p27Kip1 function: miRNAs come into play. Cell Cycle 6, 2742–2749 (2007). Important recent review of work by these authors and others showing that p27 translation is reduced by miRNA-221/222 and might contribute to p27 loss in human cancer.
  Article CAS PubMed Google Scholar
• Kedde, M. et al. RNA-binding protein Dnd1 inhibits microRNA access to target mRNA. Cell 131, 1273–1286 (2007).
  Article CAS PubMed Google Scholar
• Galardi, S. et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 282, 23716–23724 (2007).
  Article CAS PubMed Google Scholar
• Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257–2261 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Visone, R. et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr. Relat. Cancer 14, 791–798 (2007).
  Article CAS PubMed Google Scholar
• Calin, G. A. et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793–1801 (2005). References 42–44 and others within reference 38 demonstrate overexpression of miRNA-221/222 in human neoplasia.
  Article CAS PubMed Google Scholar
• Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nature Rev. Cancer 6, 369–381 (2006). Important review of primary work by these authors and others that covers proteolytic mechanisms governing p27 degradation.
  Article CAS Google Scholar
• Bloom, J. & Pagano, M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin. Cancer Biol. 13, 41–47 (2003). Important conceptual review of p27 proteolysis by the SCF SKP2 ubiquitin ligase pathway.
  Article CAS PubMed Google Scholar
• Sabile, A. et al. Regulation of p27 degradation and S-phase progression by Ro52 RING finger protein. Mol. Cell. Biol. 26, 5994–6004 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Pavletich, N. P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 287, 821–828 (1999).
  Article CAS PubMed Google Scholar
• Chu, I. et al. p27 phosphorylation by Src regulates inhibition of cyclin E–Cdk2. Cell 128, 281–294 (2007). References 5 and 49 first showed that tyrosine phosphorylation of p27 has effects on Cdk binding and promotes SCF SKP2 -mediated p27 proteolysis.
  Article CAS PubMed PubMed Central Google Scholar
• Russo, A. A., Jeffrey, P. D., Patten, A. K., Massague, J. & Pavletich, N. P. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382, 325–331 (1996). Solved the crystal structure of the N-terminal fragment of p27 bound to cyclin A–CDK2.
  Article CAS PubMed Google Scholar
• Malek et al. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 413, 323–327 (2001)
  Article CAS PubMed Google Scholar
• Bondar, T. et al. Cu14A and DDB1 associate with Skp2 to target p27Kip1 for proteolysis involving the COP9 signalosome. Mol. Cell. Biol. 26, 2531–2539 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Tomoda, K., Kubota, Y. & Kato, J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398, 160–165 (1999). References 52 & 53 indicate that p27 proteolysis might be linked to COP9 signalosome function.
  Article CAS PubMed Google Scholar
• Boehm, M. et al. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J. 21, 3390–3401 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Deng, X., Mercer, S. E., Shah, S., Ewton, D. Z. & Friedman, E. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G0 by Mirk/dyrk1B kinase. J. Biol. Chem. 279, 22498–22504 (2004).
  Article CAS PubMed Google Scholar
• Rodier, G. et al. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 20, 6672–6682 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Ishida, N. et al. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J. Biol. Chem. 277, 14355–14358 (2002).
  Article CAS PubMed Google Scholar
• Connor, M. K. et al. CRM1/Ran-mediated nuclear export of p27Kip1 involves a nuclear export signal and links p27 export and proteolysis. Mol. Biol. Cell 14, 201–213 (2003). References 56–58 demonstrate that p27 is exported from the nucleus in a CRM1-dependent manner and show serine 10 phosphorylation promotes nuclear export.
  Article CAS PubMed PubMed Central Google Scholar
• Besson, A. et al. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 20, 47–64 (2006). This paper showed that serine 10 phosphorylation regulates p27 stability in G0.
  Article CAS PubMed PubMed Central Google Scholar
• Liang, J. et al. The energy sensing LKB-1–AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Nature Cell Biol. 9, 218–224 (2007).
  Article CAS PubMed Google Scholar
• Kossatz, U. et al. C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J. 25, 5159–5170 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kotake, Y., Nakayama, K., Ishida, N. & Nakayama, K. I. Role of serine 10 phosphorylation in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 mutation. J. Biol. Chem. 280, 1095–1102 (2005). This paper showed that serine 10 phosphorylation regulates p27 stability in G0.
  Article CAS PubMed Google Scholar
• Ishizawar, R. & Parsons, S. J. c-Src and cooperating partners in human cancer. Cancer Cell 6, 209–214 (2004).
  Article CAS PubMed Google Scholar
• Pegram, M. D., Pauletti, G. & Slamon, D. J. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65–77 (1998).
  Article CAS PubMed Google Scholar
• Arteaga, C. L. & Baselga, J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin. Cancer Res. 9, 1579–1589 (2003).
  CAS PubMed Google Scholar
• Spataro, V. J. et al. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial, V. Cancer 97, 1591–1600 (2003).
  Article CAS PubMed Google Scholar
• Newman, L. et al. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol. Carcinog. 30, 169–175 (2001).
  Article CAS PubMed Google Scholar
• Donovan, J. C., Milic, A. & Slingerland, J. M. Constitutive MEK/MAPK activation leads to p27Kip1 deregulation and antiestrogen resistance in human breast cancer cells. J. Biol. Chem. 276, 40888–40895 (2001).
  Article CAS PubMed Google Scholar
• Yang, H. Y., Zhou, B. P., Hung., M. C. & Lee, M. H. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J. Biol. Chem. 275, 24735–24739 (2000). This paper demonstrated that p27 proteolysis is activated by overexpression of Her2.
  Article CAS PubMed Google Scholar
• Nahta, R., Takahashi, T., Ueno, N. T., Hung., M. C. & Esteva, F. J. P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 64, 3981–3986 (2004).
  Article CAS PubMed Google Scholar
• Busse, D. et al. Reversible G1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27KIP1 independent of MAPK activity. J. Biol. Chem. 275, 6987–6995 (2000).
  Article CAS PubMed Google Scholar
• Chu, I., Blackwell, K., Chen, S. & Slingerland, J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 65, 18–25 (2005).
  CAS PubMed Google Scholar
• Moller, M. B., Skjodt, K., Mortensen, L. S. & Pedersen, N. T. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. Br. J. Haematol. 105, 730–736 (1999).
  Article CAS PubMed Google Scholar
• Tsihlias, J., Kapusta, L. & Slingerland, J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu. Rev. Med. 50, 401–423 (1999).
  Article CAS PubMed Google Scholar
• Andreu, E. J. et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 65, 3264–3272 (2005).
  Article CAS PubMed Google Scholar
• Donato, N. J. et al. BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101, 690–698 (2003).
  Article CAS PubMed Google Scholar
• Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
  Article CAS Google Scholar
• Tsutsui, S. et al. Inactivation of PTEN is associated with a low p27Kip1 protein expression in breast carcinoma. Cancer 104, 2048–2053 (2005).
  Article CAS PubMed Google Scholar
• Latres, E. et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl Acad. Sci. USA 98, 2515–2520 (2001). First demonstration that SKP2 is overexpressed in human lymphoma and that SKP2 overexpression promotes lymphoma progression in a mouse model in vivo.
  Article CAS PubMed PubMed Central Google Scholar
• Chiarle, R. et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 95, 619–626 (2000).
  CAS PubMed Google Scholar
• Hershko, D. et al. Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 91, 1745–1751 (2001).
  Article CAS PubMed Google Scholar
• Shapira, M. et al. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 103, 1336–1346 (2005).
  Article CAS PubMed Google Scholar
• Signoretti, S. et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110, 633–641 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Shintani, S. et al. Skp2 and Jab1 expression are associated with inverse expression of p27KIP1 and poor prognosis in oral squamous cell carcinomas. Oncology 65, 355–362 (2003).
  Article CAS PubMed Google Scholar
• Kudo, Y. et al. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res. 61, 7044–7047 (2001).
  CAS PubMed Google Scholar
• Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl Acad. Sci. USA 98, 5043–5048 (2001). First demonstrated overexpression and oncogenicity of SKP2 in human epithelial cancer.
  Article CAS PubMed PubMed Central Google Scholar
• Drobnjak, M. et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin. Cancer Res. 9, 2613–2619 (2003).
  CAS PubMed Google Scholar
• Yokoi, S. et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am. J. Pathol. 161, 207–216 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Masuda, T. A. et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 62, 3819–3825 (2002).
  CAS PubMed Google Scholar
• Nakayama, K. et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev. Cell 6, 661–672 (2004).
  Article CAS PubMed Google Scholar
• Kossatz, U. et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 18, 2602–2607 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Catzavelos, C. et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Med. 3, 227–230 (1997).
  Article CAS PubMed Google Scholar
• Porter, P. L. et al. Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 3, 222–225 (1997).
  Article CAS PubMed Google Scholar
• Tan, P. et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res. 57, 1259–1263 (1997). References 92–94 were the first to demonstrate that p27 levels are frequently reduced in human breast cancer and that this is prognostic for poor patient outcome on multivariate analysis.
  CAS PubMed Google Scholar
• Zeng, Y., Hirano, K., Hirano, M., Nishimura, J. & Kanaide, H. Minimal requirements for the nuclear localization of p27Kip1, a cyclin-dependent kinase inhibitor. Biochem. Biophys. Res. Commun. 274, 37–42 (2000).
  Article CAS PubMed Google Scholar
• LaBaer, J. et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11, 847–862 (1997).
  Article CAS PubMed Google Scholar
• Cheng, M. et al. The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18, 1571–1583 (1999). References 96 and 97 provide biochemical and genetic evidence that p27 and p21 regulate the assembly of D-type cyclin–Cdk complexes.
  Article CAS PubMed PubMed Central Google Scholar
• Liang, J. et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Med. 8, 1153–1160 (2002). This paper showed that Akt phosphorylated p27 to impair its nuclear import.
  Article CAS PubMed Google Scholar
• Shin, I., Rotty, J., Wu, F. Y. & Arteaga, C. L. Phosphorylation of p27Kip1 at Thr-157 interferes with its association with importin alpha during G1 and prevents nuclear re-entry. J. Biol. Chem. 280, 6055–6063 (2005).
  Article CAS PubMed Google Scholar
• Sekimoto, T., Fukumoto, M. & Yoneda, Y. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27Kip1. EMBO J. 23, 1934–1942 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Fujita, N., Sato, S., Katayama, K. & Tsuruo, T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 277, 28706–28713 (2002).
  Article CAS PubMed Google Scholar
• Fujita, N., Sato, S. & Tsuruo, T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 278, 49254–49260 (2003).
  Article CAS PubMed Google Scholar
• Kardinal, C. et al. Tyrosine phosphorylation modulates binding preference to cyclin-dependent kinases and subcellular localization of p27Kip1 in the acute promyelocytic leukemia cell line NB4. Blood 107, 1133–1140 (2006).
  Article CAS PubMed Google Scholar
• Soos, T. J. et al. Formation of p27–CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 7, 135–146 (1996).
  CAS PubMed Google Scholar
• Zhang, H., Hannon, G. & Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8, 1750–1758 (1994).
  Article CAS PubMed Google Scholar
• Nagahara, H. et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT–p27Kip1 induces cell migration. Nature Med. 4, 1449–1452 (1998).
  Article CAS PubMed Google Scholar
• Cheng, M., Sexl, V., Sherr, C. J. & Roussel, M. F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl Acad. Sci. USA. 95, 1091–1096 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, X. et al. Disruption of TGF-β growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene 19, 5926–5935 (2000).
  Article CAS PubMed Google Scholar
• Viglietto, G. et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nature Med. 8, 1136–1144 (2002).
  Article CAS PubMed Google Scholar
• Shin, I. et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nature Med. 8, 1145–1152 (2002). References 98, 109 and 110 were published together and all showed that cytoplasmic mislocalization of p27 in human breast cancer was associated with activation of Akt.
  Article CAS PubMed Google Scholar
• Viglietto, G. & Fusco, A. Understanding p27kip1 deregulation in cancer: down-regulation or mislocalization? Cell Cycle 1, 394–400 (2002).
  Article CAS PubMed Google Scholar
• Motti, M. L., De Marco, C., Califano, D., Fusco, A. & Viglietto, G. Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell Cycle 3, e89–e95 (2004).
  Article Google Scholar
• Psyrri, A. et al. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin. Cancer Res. 11, 8384–8390 (2005).
  Article CAS PubMed Google Scholar
• Baldassarre, G. et al. p27Kip1-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 7, 51–63 (2005).
  Article CAS PubMed Google Scholar
• McAllister, S. S., Becker-Hapak, M., Pintucci, G., Pagano, M. & Dowdy, S. F. Novel p27kip1 C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol. Cell Biol. 23, 216–228 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Wu, F. Y. et al. Reduction of cytosolic p27Kip1 inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 66, 2162–2172 (2006).
  Article CAS PubMed Google Scholar
• Denicourt, C., Saenz, C. C., Datnow, B., Cui, X. S. & Dowdy, S. F. Relocalized p27KiP1 tumor suppressor functions as a cytoplasmic metastatic oncogene in melanoma. Cancer Res. 67, 9238–9243 (2007).
  Article CAS PubMed Google Scholar
• Besson, A. et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 21, 1731–1746 (2007). Identified a novel pro-oncogenic action of p27 to promote expansion of cells with self-renewal capacity or tumour-initiating function.
  Article CAS PubMed PubMed Central Google Scholar
• Jordan, R., Bradley, G. & Slingerland, J. M. Reduced levels of the cell-cycle inhibitor p27KIP1 in epithelial dysplasia and carcinoma of the oral cavity. Am. J. Pathol. 152, 1–6 (1998).
  Google Scholar
• De Paola, F. et al. p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions. J. Pathol. 196, 26–31 (2002).
  Article CAS PubMed Google Scholar
• Moriya, T. et al. Immunohistochemical analysis of Ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast: its correlation to histologic findings in 43 cases. Mod. Pathol. 13, 13–18 (2000).
  Article CAS PubMed Google Scholar
• Oh, Y. L. et al. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Path. Int. 51, 94–99 (2001).
  Article CAS Google Scholar
• Han, S. et al. Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res. Treat. 55, 161–167 (1999).
  Article CAS PubMed Google Scholar
• Massarelli, E. et al. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer 103, 952–959 (2005).
  Article CAS PubMed Google Scholar
• Pruneri, G. et al. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J. Clin. Oncol. 17, 3150–3159 (1999).
  Article CAS PubMed Google Scholar
• Vis, A. N. et al. Prognostic value of cell cycle proteins p27kip1 and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J. Urol. 164, 2156–2161 (2000).
  Article CAS PubMed Google Scholar
• Cordon-Cardo, C. et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl Cancer Inst. 90, 1284–1291 (1998).
  Article CAS PubMed Google Scholar
• Tsihlias, J. et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58, 542–548 (1998).
  CAS PubMed Google Scholar
• Sui, L. et al. Implication of malignancy and prognosis of p27Kip1, Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol. Oncol. 83, 56–63 (2001).
  Article CAS PubMed Google Scholar
• Korkolopoulou, P. et al. The combined evaluation of p27Kip1 and Ki-67 expression provides independent information on overall survival of ovarian carcinoma patients. Gynecol. Oncol. 85, 404–414 (2002).
  Article PubMed Google Scholar
• Yatabe, Y. et al. p27Kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res. 58, 1042–1047 (1998).
  CAS PubMed Google Scholar
• Ishihara, S. et al. The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens. Lung Cancer 26, 187–194 (1999).
  Article CAS PubMed Google Scholar
• Hommura, F. et al. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin. Cancer Res. 6, 4073–4081 (2000).
  CAS PubMed Google Scholar
• Tsukamoto, S. et al. Reduced expression of cell-cycle regulator p27Kip1 correlates with a shortened survival in non-small cell lung cancer. Lung Cancer 34, 83–90 (2001).
  Article CAS PubMed Google Scholar
• Hayashi, H. et al. High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer 34, 59–65 (2001).
  Article CAS PubMed Google Scholar
• Hirabayashi, H. et al. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53. J. Surg. Oncol. 81, 177–184 (2002).
  Article PubMed Google Scholar
• Takahashi, S. et al. Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases. Int. J. Clin. Oncol. 7, 349–355 (2002).
  Article CAS PubMed Google Scholar
• Catzavelos, C. et al. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a potential prognostic factor independent of ras. Cancer Res. 59, 684–688 (1999).
  CAS PubMed Google Scholar
• Esposito, V. et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57, 3381–3385 (1997).
  CAS PubMed Google Scholar
• Hirsch, F. R. et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798–3807 (2003).
  Article CAS PubMed Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
  Article CAS PubMed Google Scholar
• Amann, J. et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65, 226–235 (2005).
  CAS PubMed Google Scholar
• Anayama, T., Furihata, M., Ishikawa, T., Ohtsuki, Y. & Ogoshi, S. Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. Int. J. Cancer 79, 439–443 (1998).
  Article CAS PubMed Google Scholar
• Fan, G. K. et al. Expression of protein p27 is associated with progression and prognosis in laryngeal cancer. Laryngoscope 109, 815–820 (1999).
  Article CAS PubMed Google Scholar
• Itami, A., Shimada, Y., Watanabe, G. & Imamura, M. Prognostic value of p27Kip1 and CyclinD1 expression in esophageal cancer. Oncology 57, 311–317 (1999).
  Article CAS PubMed Google Scholar
• Mineta, H. et al. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma. Cancer 85, 1011–1017 (1999).
  Article CAS PubMed Google Scholar
• Fujieda, S. et al. Expression of p27 is associated with Bax expression and spontaneous apoptosis in oral and oropharyngeal carcinoma. Int. J. Cancer 84, 315–320 (1999).
  Article CAS PubMed Google Scholar
• Venkatesan, T. K. et al. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope 109, 1329–1333 (1999).
  Article CAS PubMed Google Scholar
• Shamma, A. et al. Loss of p27KIP1 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Oncology 58, 152–158 (2000).
  Article CAS PubMed Google Scholar
• Kagawa, Y., Yoshida, K., Hirai, T. & Toge, T. Significance of the expression of p27Kip1 in esophageal squamous cell carcinomas. Dis. Esophagus. 13, 179–184 (2000).
  Article CAS PubMed Google Scholar
• Tamura, N. et al. Cyclin-dependent kinase inhibitor p27 is related to cell proliferation and prognosis in laryngeal squamous cell carcinomas. J. Laryngol. Otol. 115, 400–406 (2001).
  Article CAS PubMed Google Scholar
• Kuo, M. Y. et al. Prognostic role of p27Kip1 expression in oral squamous cell carcinoma in Taiwan. Oral Oncol. 38, 172–178 (2002).
  Article CAS PubMed Google Scholar
• Korkmaz, H. et al. Prognostic significance of G1 cell-cycle inhibitors in early laryngeal cancer. Am. J. Otolaryngol. 26, 77–82 (2005).
  Article CAS PubMed Google Scholar
• Langer, R. et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J. Clin. Pathol. 59, 631–634 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Loda, M. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3, 231–234 (1997). Among the first studies to show loss of p27 protein expression is prognostic in human cancer. Showed that lysates from colon cancers with low p27 levels exhibit proteolytic activity toward recombinant p27 in vitro.
  Article CAS PubMed Google Scholar
• Belluco, C. et al. Absence of the cell cycle inhibitor p27Kip1 protein predicts poor outcome in patients with stage I–III colorectal cancer. Ann. Surg. Oncol. 6, 19–25 (1999).
  Article CAS PubMed Google Scholar
• Palmqvist, R., Stenling, R., Oberg, A. & Landberg, G. Prognostic significance of p27Kip1 expression in colorectal cancer: a clinico-pathological characterization. J. Pathol. 188, 18–23 (1999).
  Article CAS PubMed Google Scholar
• Tenjo, T. et al. Prognostic significance of p27kip1 protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 58, 45–51 (2000).
  Article CAS PubMed Google Scholar
• Rossi, H. A. et al. The prognostic value of invariant chain (Ii) and her-2/neu expression in curatively resected colorectal cancer. Cancer J. 8, 268–275 (2002).
  Article PubMed Google Scholar
• Noguchi, T. et al. Prognostic significance of p27/kip1 and apoptosis in patients with colorectal carcinoma. Oncol. Rep. 10, 827–831 (2003).
  CAS PubMed Google Scholar
• Galizia, G. et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin. Cancer Res. 10, 3490–3499 (2004).
  Article CAS PubMed Google Scholar
• Manne, U. et al. Prognostic significance of p27(kip-1) expression in colorectal adenocarcinomas is associated with tumor stage. Clin. Cancer Res. 10, 1743–1752 (2004).
  Article CAS PubMed Google Scholar
• Rosati, G., Chiacchio, R., Reggiardo, G., De Sanctis, D. & Manzione, L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol. 25, 258–263 (2004).
  Article CAS PubMed Google Scholar
• Wu, J. T. et al. Prognostic significance of DCC and p27Kip1 in colorectal cancer. Appl. Immunohistochem. Mol. Morphol. 13, 45–54 (2005).
  Article CAS PubMed Google Scholar
• Watson, N. F. et al. Cytoplasmic expression of p27kip1 is associated with a favourable prognosis in colorectal cancer patients. World J. Gastroenterol. 12, 6299–6304 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Sarli, L. et al. Loss of p27 expression and microsatellite instability in sporadic colorectal cancer. Surg. Oncol. 15, 97–106 (2006).
  Article PubMed Google Scholar
• Ciaparrone, M. et al. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res. 58, 114–122 (1998).
  CAS PubMed Google Scholar
• Cheng, J. D., Werness, B. A., Babb, J. S. & Meropol, N. J. Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin. Cancer Res. 5, 1057–1062 (1999).
  CAS PubMed Google Scholar
• Galizia, G. et al. Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis. Colon Rectum 47, 1904–1914 (2004).
  Article PubMed Google Scholar
• Yang, R. M. et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol. 159, 941–945 (1998).
  Article CAS PubMed Google Scholar
• Cote, R. J. et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl Cancer Inst. 90, 916–920 (1998).
  Article CAS PubMed Google Scholar
• Freedland, S. J. et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J. Urol. 169, 1325–1330 (2003).
  Article CAS PubMed Google Scholar
• Li, R. et al. Biological correlates of p27 compartmental expression in prostate cancer. J. Urol. 175, 528–532 (2006).
  Article CAS PubMed Google Scholar
• Kuczyk, M. A. et al. Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer. Oncol. Rep. 8, 1401–1407 (2001).
  CAS PubMed Google Scholar
• Cheville, J. C. et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod. Pathol. 11, 324–328 (1998).
  CAS PubMed Google Scholar
• Thomas, G. V. et al. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J. Urol. 164, 1987–1991 (2000).
  Article CAS PubMed Google Scholar
• Freedland, S. J. et al. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology 61, 1187–1192 (2003).
  Article PubMed Google Scholar
• Newcomb, E. W. et al. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am. J. Pathol. 154, 119–125 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Baekelandt, M., Holm, R., Trope, C. G., Nesland, J. M. & Kristensen, G. B. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin. Cancer Res. 5, 2848–2853 (1999).
  CAS PubMed Google Scholar
• Masciullo, V. et al. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin. Cancer Res. 6, 4816–4822 (2000).
  CAS PubMed Google Scholar
• Schmider-Ross, A. et al. Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. J. Cancer Res. Clin. Oncol. 132, 163–170 (2006).
  Article CAS PubMed Google Scholar
• Barnes, A. et al. Expression of p27kip I in breast cancer and its prognostic significance. J. Pathology 201, 451–459 (2003).
  Article CAS Google Scholar
• Gillett, C. E., Smith, P., Peters, G., Lu, X. & Barnes, D. M. Cyclin-dependent kinase inhibitor p27Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma. J. Pathol. 187, 200–206 (1999).
  Article CAS PubMed Google Scholar
• Barbareschi, M. et al. p27kip1 expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int. J. Cancer 89, 236–241 (2000).
  Article CAS PubMed Google Scholar
• Leivonen, M., Nordling, S., Lundin, J., von Boguslawski, K. & Haglund, C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res. Treat. 67, 15–22 (2001).
  Article CAS PubMed Google Scholar
• Han, S. et al. Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J. Surg. Oncol. 83, 241–247 (2003).
  Article PubMed Google Scholar
• Porter, P. L. et al. p27Kip1 and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J. Natl Cancer Inst. 98, 1723–1731 (2006). An important paper confirming the prognostic potential of p27 and shows that p27 loss is most prognostic in ER-positive human breast cancers in retrospective analysis of samples from a prospective randomized clinical trial.
  Article CAS PubMed Google Scholar
• Wu, J. et al. Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br. J. Cancer 79, 1572–1578 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Tsuchiya, A., Zhang, G. J. & Kanno, M. Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer. J. Surg. Oncol. 70, 230–234 (1999).
  Article CAS PubMed Google Scholar
• Chappuis, P. O. et al. Germline BRCA1/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer. J. Clin. Oncol. 18, 4045–4052 (2000).
  Article CAS PubMed Google Scholar
• Nohara, T., Ryo, T., Iwamoto, S., Gon, G. & Tanigawa, N. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology 60, 94–100 (2001).
  Article CAS PubMed Google Scholar
• Pohl, G. et al. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J. Clin. Oncol. 21, 3594–3600 (2003). The first study showing the predictive potential of p27 in a prospective trial. This important study showed that reduced p27 levels correlate with poor outcome in multivariate analysis and reduced response to endocrine therapy in pre-menopausal women with breast cancer in a retrospective analysis of p27 in samples collected in a prospective clinical trial.
  Article CAS PubMed Google Scholar
• Foulkes, W. D. et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 64, 830–835 (2004).
  Article CAS PubMed Google Scholar
• Reed, W., Florems, V. A., Holm, R., Hannisdal, E. & Nesland, J. M. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch. 435, 116–124 (1999).
  Article CAS PubMed Google Scholar
• Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  Article CAS PubMed Google Scholar
• Osborne, C. K. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 51, 227–238 (1998).
  Article CAS PubMed Google Scholar
• Oka, K., Suzuki, Y. & Nakano, T. Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone: radiotherapeutic effect and prognosis. Cancer 88, 2766–2773 (2000).
  Article CAS PubMed Google Scholar
• Cariou, S. et al. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl Acad. Sci. USA 97, 9042–9046 (2000). This paper demonstrated that p27 and p21 are required for growth arrest by tamoxifen and other antioestrogens in breast cancer cells in culture.
  Article CAS PubMed PubMed Central Google Scholar
• Lane, H. A. et al. ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1–CDK2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell Biol. 20, 3210–3223 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Hayes, D. F. Prognostic and predictive factors for breast cancer: translating technology to oncology. J. Clin. Oncol. 23, 1596–1597 (2005).
  Article PubMed Google Scholar
• Van't Veer, L. J., Paik, S. & Hayes, D. F. Gene expression profiling of breast cancer: a new tumor marker. J. Clin. Oncol. 23, 1631–1635 (2005).
  Article CAS PubMed Google Scholar
• Oshita, F. et al. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer. Oncol. Rep. 7, 491–495 (2000).
  CAS PubMed Google Scholar
• Kobayashi, M., Shiraishi, T., Tonouchi, H., Miki, C. & Kusunoki, M. 5-FU improves p27-related poor prognosis in patients with Astler-Coller B2-C colorectal carcinoma. Oncol. Rep. 9, 29–33 (2002).
  CAS PubMed Google Scholar
• Prall, F., Ostwald, C., Nizze, H. & Barten, M. Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis. Appl. Immunohistochem. Mol. Morphol. 12, 111–121 (2004).
  Article PubMed Google Scholar
• Singh, S. P. et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58, 1730–1735 (1998).
  CAS PubMed Google Scholar
• Zeng, W. Q. et al. Relationships between levels of Skp2 and p27 in breast carcinomas and possible role of Skp2 as targeted therapy. Steroids 70, 770–774 (2005).
  Article CAS Google Scholar
• Chang, J. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J. Natl Cancer Inst. (in the press).
• Hattori, T. et al. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27_Kip1_. Cancer Res. 67, 10789–10795 (2007).
  Article CAS PubMed Google Scholar
• Hauck, L. et al. Protein kinase CK2 links extracellular growth factor signaling with the control of p27_Kip1_ stability in the heart. Nature Med. 14, 315–324 (2008).
  Article CAS PubMed Google Scholar